Cargando…

Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study

BACKGROUND: Little is known about prescription patterns of expensive non-recommended newer long-acting insulins (glargine 300 U/mL and degludec) for patients with type 2 diabetes mellitus (T2DM). AIM: To identify practice variation in, and practice- and patient-related characteristics associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Dankers, Marloes, Hek, Karin, Nelissen-Vrancken, Marjorie, Houweling, Sebastiaan T, Mantel-Teeuwisse, Aukje, van Dijk, Liset
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal College of General Practitioners 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172218/
https://www.ncbi.nlm.nih.gov/pubmed/35606162
http://dx.doi.org/10.3399/BJGP.2021.0581
_version_ 1784721839636873216
author Dankers, Marloes
Hek, Karin
Nelissen-Vrancken, Marjorie
Houweling, Sebastiaan T
Mantel-Teeuwisse, Aukje
van Dijk, Liset
author_facet Dankers, Marloes
Hek, Karin
Nelissen-Vrancken, Marjorie
Houweling, Sebastiaan T
Mantel-Teeuwisse, Aukje
van Dijk, Liset
author_sort Dankers, Marloes
collection PubMed
description BACKGROUND: Little is known about prescription patterns of expensive non-recommended newer long-acting insulins (glargine 300 U/mL and degludec) for patients with type 2 diabetes mellitus (T2DM). AIM: To identify practice variation in, and practice- and patient-related characteristics associated with, the prescription of newer long-acting insulins to patients with T2DM in primary care. DESIGN AND SETTING: A retrospective cohort study in Dutch general practices (Nivel Primary Care Database). METHOD: A first prescription for intermediate or long-acting insulins in 2018 was identified in patients aged ≥40 years using other T2DM drugs. Per practice, the median percentage and interquartile range (IQR) of patients with newer insulin prescriptions were calculated. Multilevel logistic regression models were constructed to calculate intraclass correlation coefficients (ICCs) and quantify the association of patient and practice characteristics with prescriptions for newer insulins (odds ratios [ORs] and 95% confidence intervals [CIs]). RESULTS: In total, 7757 patients with prescriptions for intermediate or long-acting insulins from 282 general practices were identified. A median percentage of 21.2% (IQR 12.5–36.4%) of all patients prescribed intermediate or long-acting insulins per practice received a prescription for newer insulins. After multilevel modelling, the ICC decreased from 20% to 19%. Female sex (OR 0.77, 95% CI = 0.69 to 0.87), age ≥86 years compared with 40–55 years (OR 0.22, 95% CI = 0.15 to 0.34), prescriptions for metformin (OR 0.66, 95% CI = 0.53 to 0.82), sulfonylurea (OR 0.58, 95% CI = 0.51 to 0.66), or other newer T2DM drugs (OR 3.10, 95% CI = 2.63 to 3.66), and dispensing practices (OR 1.78, 95% CI = 1.03 to 3.10) were associated with the prescription of newer insulins. CONCLUSION: The inter-practice variation in the prescription of newer insulins is large and could only be partially explained by patient- and practice-related differences. This indicates substantial opportunities for improvement.
format Online
Article
Text
id pubmed-9172218
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Royal College of General Practitioners
record_format MEDLINE/PubMed
spelling pubmed-91722182022-06-17 Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study Dankers, Marloes Hek, Karin Nelissen-Vrancken, Marjorie Houweling, Sebastiaan T Mantel-Teeuwisse, Aukje van Dijk, Liset Br J Gen Pract Research BACKGROUND: Little is known about prescription patterns of expensive non-recommended newer long-acting insulins (glargine 300 U/mL and degludec) for patients with type 2 diabetes mellitus (T2DM). AIM: To identify practice variation in, and practice- and patient-related characteristics associated with, the prescription of newer long-acting insulins to patients with T2DM in primary care. DESIGN AND SETTING: A retrospective cohort study in Dutch general practices (Nivel Primary Care Database). METHOD: A first prescription for intermediate or long-acting insulins in 2018 was identified in patients aged ≥40 years using other T2DM drugs. Per practice, the median percentage and interquartile range (IQR) of patients with newer insulin prescriptions were calculated. Multilevel logistic regression models were constructed to calculate intraclass correlation coefficients (ICCs) and quantify the association of patient and practice characteristics with prescriptions for newer insulins (odds ratios [ORs] and 95% confidence intervals [CIs]). RESULTS: In total, 7757 patients with prescriptions for intermediate or long-acting insulins from 282 general practices were identified. A median percentage of 21.2% (IQR 12.5–36.4%) of all patients prescribed intermediate or long-acting insulins per practice received a prescription for newer insulins. After multilevel modelling, the ICC decreased from 20% to 19%. Female sex (OR 0.77, 95% CI = 0.69 to 0.87), age ≥86 years compared with 40–55 years (OR 0.22, 95% CI = 0.15 to 0.34), prescriptions for metformin (OR 0.66, 95% CI = 0.53 to 0.82), sulfonylurea (OR 0.58, 95% CI = 0.51 to 0.66), or other newer T2DM drugs (OR 3.10, 95% CI = 2.63 to 3.66), and dispensing practices (OR 1.78, 95% CI = 1.03 to 3.10) were associated with the prescription of newer insulins. CONCLUSION: The inter-practice variation in the prescription of newer insulins is large and could only be partially explained by patient- and practice-related differences. This indicates substantial opportunities for improvement. Royal College of General Practitioners 2022-05-24 /pmc/articles/PMC9172218/ /pubmed/35606162 http://dx.doi.org/10.3399/BJGP.2021.0581 Text en © The Authors https://creativecommons.org/licenses/by/4.0/This article is Open Access: CC BY 4.0 licence (http://creativecommons.org/licences/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Research
Dankers, Marloes
Hek, Karin
Nelissen-Vrancken, Marjorie
Houweling, Sebastiaan T
Mantel-Teeuwisse, Aukje
van Dijk, Liset
Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study
title Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study
title_full Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study
title_fullStr Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study
title_full_unstemmed Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study
title_short Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study
title_sort newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172218/
https://www.ncbi.nlm.nih.gov/pubmed/35606162
http://dx.doi.org/10.3399/BJGP.2021.0581
work_keys_str_mv AT dankersmarloes newerlongactinginsulinprescriptionsforpatientswithtype2diabetesprevalenceandpracticevariationinaretrospectivecohortstudy
AT hekkarin newerlongactinginsulinprescriptionsforpatientswithtype2diabetesprevalenceandpracticevariationinaretrospectivecohortstudy
AT nelissenvranckenmarjorie newerlongactinginsulinprescriptionsforpatientswithtype2diabetesprevalenceandpracticevariationinaretrospectivecohortstudy
AT houwelingsebastiaant newerlongactinginsulinprescriptionsforpatientswithtype2diabetesprevalenceandpracticevariationinaretrospectivecohortstudy
AT mantelteeuwisseaukje newerlongactinginsulinprescriptionsforpatientswithtype2diabetesprevalenceandpracticevariationinaretrospectivecohortstudy
AT vandijkliset newerlongactinginsulinprescriptionsforpatientswithtype2diabetesprevalenceandpracticevariationinaretrospectivecohortstudy